JAKARTA – On the occasion of the 61st National Health Day (HKN), Dexa Medica achieved a significant milestone by receiving the Karya Anak Bangsa Award from the Ministry of Health of the Republic of Indonesia, recognizing it as the pharmaceutical industry with the highest number of clinical trials for natural-based drugs in the country.
The award was presented during the Health Innovation Festival (HAI-Fest) 2025 held at Kartika Expo Balai Kartini, Jakarta, on Monday, December 8, 2025.
V. Hery Sutanto, President Director of PT Dexa Medica, stated that the award is a recognition of the long-standing commitment of the national pharmaceutical industry in developing drugs derived from Indonesia’s natural wealth, while also affirming Dexa’s role in improving access to affordable medicines for the community.
“This award is not only a recognition of our hard work but also proof that innovations by local talents can meet global scientific standards and deliver tangible benefits to public health,” he said.
Prof. Raymond Tjandrawinata, Business Development and Scientific Affairs Director of Dexa Medica, emphasized that clinical trials are not merely a scientific process but also a moral responsibility to ensure the safety and efficacy of therapies for millions of patients.
“Dexa Group’s commitment to conducting clinical trials demonstrates that health innovations by local talents can not only compete globally but also lead the transformation of national healthcare toward pharmaceutical self-sufficiency and a prosperous Indonesia by 2045,” said Prof. Raymond.
Preparing Indonesia’s Golden Generation
The HAI-Fest 2025 was inaugurated by Deputy Minister of Health Prof. Dante Saksono Harbuwono, who highlighted the importance of preparing Indonesia’s population for productive life by 2045.
“We have two decades to ensure they grow into a healthy, strong, intelligent, and globally competitive generation,” he stated. He added that downstream development in the healthcare industry is a critical strategy to ensure Indonesia becomes not just a consumer, but also a producer of medicines, vaccines, and medical devices.
Prof. Dante also noted key achievements of the national health sector, including the Free Health Check Program (CKG) reaching over 62 million citizens, detection of 750,000 new TB cases, and the accelerated construction of 22 out of 66 modern hospitals. According to him, the ongoing healthcare transformation is shifting Indonesia toward a proactive, preventive, and technology-based model, with innovations from industries like Dexa Group playing a strategic role.
Building a Research Ecosystem at Dexa Laboratories of Biomolecular Sciences
Dexa Group’s Integrative Modern Natural Medicine Research (OMAI) is supported by advanced technologies such as the Tandem Chemistry Expression Bioassay System, implemented by scientists at Dexa Laboratories of Biomolecular Sciences (DLBS), with preclinical and clinical trials conducted across multiple cities in Indonesia.
Prof. Raymond reaffirmed the importance of scientific discipline in all processes. “Every OMAI discovery must meet the highest scientific standards because safety and efficacy are non-negotiable,” he emphasized. This philosophy underpins why OMAI Dexa Group’s research has been integrated into national clinical guidelines.
The results of this research are now evident in phytopharmaceutical products such as DLBS1033 (DISOLF), included in the 2025 Stroke Guidelines by PERDOSNI, which has been proven to improve neurological function in ischemic stroke patients with minimal side effects.
The Inlacin product has also received strong recommendations for managing insulin-resistant PCOS and controlling glycemia in prediabetes and type 2 diabetes. Other OMAI innovations, including triple-action gastroprotectors and new hepatoprotectors, further consolidate Dexa’s position as a scientific leader in the development of modern natural-based therapies.